In vivo neurochemistry of the brain in schizophrenia as revealed by magnetic resonance spectroscopy
暂无分享,去创建一个
[1] R G Shulman,et al. Nuclear magnetic resonance imaging and spectroscopy of human brain function. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[2] C. Cotman,et al. Excitatory amino acid receptors in schizophrenia. , 1993, Schizophrenia bulletin.
[3] E. Purcell,et al. Resonance Absorption by Nuclear Magnetic Moments in a Solid , 1946 .
[4] C. Hudson,et al. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia , 1993, Synapse.
[5] T. Brown,et al. Metabolic characterization of human non-Hodgkin's lymphomas in vivo with the use of proton-decoupled phosphorus magnetic resonance spectroscopy. , 1995, Cancer research.
[6] Tetsuya Takano,et al. Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia , 1994, Biological Psychiatry.
[7] Paul J. Harrison,et al. Decreased hippocampal expression of a glutamate receptor gene in schizophrenia , 1991, The Lancet.
[8] Roger J. Ordidge,et al. Image-selected in Vivo spectroscopy (ISIS). A new technique for spatially selective nmr spectroscopy , 1986 .
[9] J. Waddington,et al. MAGNETIC RESONANCE IMAGING AND SPECTROCOPY IN SCHIZOPHRENIA , 1990 .
[10] T. Inubushi,et al. Alterations in brain phosphorous metabolism in bipolar disorder detected by in vivo 31P and 7Li magnetic resonance spectroscopy. , 1993, Journal of affective disorders.
[11] T. Inubushi,et al. Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia , 1994, Psychiatry Research: Neuroimaging.
[12] K. Behar,et al. Analysis of macromolecule resonances in 1H NMR spectra of human brain , 1994, Magnetic resonance in medicine.
[13] J. Callicott,et al. 460. Proton magnetic resonance spectroscopic imaging in drug free patients with schizophrenia: Regional neuronal damage , 1996, Biological Psychiatry.
[14] T. Asakura,et al. Study of chronic schizophrenics using 31P magnetic resonance chemical shift imaging , 1992, Acta psychiatrica Scandinavica.
[15] I. Feinberg,et al. Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? , 1982, Journal of psychiatric research.
[16] J. Coyle,et al. N-Acetylaspartate in neuropsychiatric disorders , 1995, Progress in Neurobiology.
[17] Jens Frahm,et al. Stimulated echo imaging , 1985 .
[18] T. Cooper,et al. Dopamine blockade and clinical response: evidence for two biological subgroups of schizophrenia. , 1989, The American journal of psychiatry.
[19] J. Musser,et al. Phospholipase A2: function and pharmacological regulation. , 1987, Biochemical pharmacology.
[20] P A Bottomley,et al. Human in vivo NMR spectroscopy in diagnostic medicine: clinical tool or research probe? , 1989, Radiology.
[21] G. Reynolds,et al. ASYMMETRICAL LOSS OF GLUTAMATE RECEPTOR SUBTYPE IN LEFT HIPPOCAMPUS IN SCHIZOPHRENIA , 1988, The Lancet.
[22] B. Bogerts,et al. Basal Ganglia and Limbic System Pathology in Schizophrenia: A Morphometric Study of Brain Volume and Shrinkage , 1985 .
[23] Toshiro Fujimoto,et al. Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report , 1995, Psychiatry Research: Neuroimaging.
[24] E. Andrew. A historical review of NMR and its clinical applications. , 1984, British Medical Bulletin.
[25] D. Ingvar,et al. ABNORMALITIES OF CEREBRAL BLOOD FLOW DISTRIBUTION IN PATIENTS WITH CHRONIC SCHIZOPHRENIA , 1974, Acta psychiatrica Scandinavica.
[26] S. Stahl,et al. 18Fluorodeoxyglucose PET in schizophrenia , 1985, Psychiatry Research.
[27] D. Weinberger,et al. Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia. IV. Further evidence for regional and behavioral specificity. , 1988, Archives of general psychiatry.
[28] T. Gasser,et al. Multidimensional analysis of the concentrations of 17 substances in the CSF of schizophrenics and controls , 1985, Biological Psychiatry.
[29] J. Waddington,et al. Magnetic Resonance Imaging and Spectroscopy in Schizophrenia , 1990, British Journal of Psychiatry.
[30] A. Stoll,et al. Variability of brain lithium levels during maintenance treatment: A magnetic resonance spectroscopy study , 1995, Biological Psychiatry.
[31] M. LeMay,et al. Abnormalities of the left temporal lobe and thought disorder in schizophrenia. A quantitative magnetic resonance imaging study. , 1992, The New England journal of medicine.
[32] J. Pettegrew,et al. Nmr Spectroscopy in Psychiatric Brain Disorders , 1995 .
[33] M. Bárány,et al. Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients , 1992, Schizophrenia Research.
[34] W. W. Hansen,et al. The Nuclear Induction Experiment , 1946 .
[35] N. Alpert,et al. In vivo imaging of neuromodulatory synaptic transmission using PET: A review of relevant neurophysiology , 1995 .
[36] J. Callicott,et al. 461. Reproducibility of proton magnetic resonance spectroscopic imaging in patients with schizophrenia and normal controls , 1996, Biological Psychiatry.
[37] G. Fein,et al. Abnormal frontal lobe phosphorous metabolism in bipolar disorder. , 1995, The American journal of psychiatry.
[38] P. Kinnunen,et al. Increased serum phospholipase A2 activity in schizophrenia: a replication study. , 1990, Biological psychiatry.
[39] A. Carlsson,et al. Interactions between glutamatergic and monoaminergic systems within the basal ganglia-implications for schizophrenia and Parkinson's disease , 1990, Trends in Neurosciences.
[40] D. R. Wilkie,et al. CEREBRAL ENERGY METABOLISM STUDIED WITH PHOSPHORUS NMR SPECTROSCOPY IN NORMAL AND BIRTH-ASPHYXIATED INFANTS , 1984, The Lancet.
[41] K. Uğurbil,et al. NMR chemical shift imaging in three dimensions. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[42] T. Perry. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction , 1982, Neuroscience Letters.
[43] R. Lenkinski,et al. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. , 1994, Academic radiology.
[44] R Jagoe,et al. Postmortem evidence of structural brain changes in schizophrenia. Differences in brain weight, temporal horn area, and parahippocampal gyrus compared with affective disorder. , 1986, Archives of general psychiatry.
[45] P. Williamson,et al. Membrane phospholipid metabolism and schizophrenia: an in vivo 31P-MR spectroscopy study , 1994, Schizophrenia Research.
[46] G. Fein,et al. Asymmetry of temporal lobe phosphorous metabolism in schizophrenia: A 31Phosphorous magnetic resonance spectroscopic imaging study , 1995, Biological Psychiatry.
[47] L. Bigelow,et al. Quantitative Brain Measurements in Chronic Schizophrenia , 1972, British Journal of Psychiatry.
[48] S. Deutsch,et al. A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. , 1989, Clinical neuropharmacology.
[49] P Schmalbrock,et al. Proton Magnetic Resonance Spectroscopy (1H MRS) of the Hippocampal Formation in Schizophrenia: A Pilot Study , 1994, British Journal of Psychiatry.
[50] L. DeLisi,et al. Increased temporal lobe glucose use in chronic schizophrenic patients , 1989, Biological Psychiatry.
[51] J. Coyle,et al. Immunocytochemical localization of N-acetyl-aspartate with monoclonal antibodies , 1991, Neuroscience.
[52] J. D. Stevens. The Distribution of the Phospholipid Fractions in the Red Cell Membrane of Schizophrenics , 1972 .
[53] Jullie W Pan,et al. Detection of brain glutamate and glutamine in spectroscopic images at 4.1 T , 1994, Magnetic resonance in medicine.
[54] T. Inubushi,et al. Brain phosphorous metabolism in depressive disorders detected by phosphorus-31 magnetic resonance spectroscopy. , 1992, Journal of affective disorders.
[55] R. B. Moon,et al. Determination of intracellular pH by 31P magnetic resonance. , 1973, The Journal of biological chemistry.
[56] G. Fein,et al. Basal ganglia phosphorous metabolism in chronic schizophrenia. , 1995, The American journal of psychiatry.
[57] D'Adamo Af,et al. Acetyl transport mechanisms. Involvement of N-acetyl aspartic acid in de novo fatty acid biosynthesis in the developing rat brain. , 1968 .
[58] J. Waddington,et al. Magnetic resonance spectroscopy in Schizophrenia: A nascent technology for a neurodevelopmental dirorder? , 1994, Biological Psychiatry.
[59] G. Fein,et al. Decreased temporal lobe phosphomonoesters in bipolar disorder. , 1995, Journal of affective disorders.
[60] Hart,et al. Anatomy and metabolism of the normal human brain studied by magnetic resonance at 1.5 Tesla. , 1984, Radiology.
[61] P F Renshaw,et al. A technique for detecting GABA in the human brain with PRESS localization and optimized refocusing spectral editing radiofrequency pulses , 1996, Magnetic resonance in medicine.
[62] Stephen Ashwal,et al. Proton Magnetic Resonance Spectroscopy: An Emerging Technology in Pediatric Neurology Research , 1998, Pediatric Research.
[63] D. I. Hoult,et al. Observation of tissue metabolites using 31P nuclear magnetic resonance , 1974, Nature.
[64] W. A. Adams,et al. In vivo solvent-suppressed localized hydrogen nuclear magnetic resonance spectroscopy: a window to metabolism? , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[65] M. Berridge. Inositol trisphosphate and diacylglycerol as second messengers. , 1984, The Biochemical journal.
[66] J. Collinge,et al. Decreased Hippocampal Expression of a Glutamate Receptor Gene in Schizophrenia , 1991, British Journal of Psychiatry.
[67] M. Keshavan,et al. Phosphorus 31 magnetic resonance spectroscopy detects altered brain metabolism before onset of schizophrenia. , 1991, Archives of general psychiatry.
[68] P. V. van Zijl,et al. Comparison of single‐shot localization methods (steam and press) for In vivo proton NMR spectroscopy , 1989, NMR in biomedicine.
[69] J. Kelsoe,et al. Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study. , 1989, The American journal of psychiatry.
[70] C. Karson,et al. Fluoxetine and trifluoperazine in human brain: A 19F-nuclear magnetic resonance spectroscopy study , 1992, Psychiatry Research: Neuroimaging.
[71] M. Keshavan,et al. Frontal lobe metabolism and cerebral morphology in schizophrenia: 31P MRS and MRI studies , 1993, Schizophrenia Research.
[72] G. Fein,et al. 31Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia , 1994, Biological Psychiatry.
[73] D. Weinberger,et al. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia , 1987, Psychiatry Research.
[74] Roger J. Ordidge,et al. Image selected in-vivo spectroscopy (ISIS) , 1985 .
[75] P. Tofts,et al. A critical assessment of methods of measuring metabolite concentrations by NMR spectroscopy , 1988, NMR in biomedicine.
[76] M. Keshavan,et al. Magnetic resonance spectroscopy in psychiatry: potential, pitfalls, and promise. , 1991, The American journal of psychiatry.
[77] J. Waddington,et al. Initial investigation of the left temporoparietal region in schizophrenia by 31P magnetic resonance spectroscopy , 1991, Biological Psychiatry.
[78] G J Barker,et al. Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia , 1995, Psychological Medicine.
[79] M S Buchsbaum,et al. Cerebral glucography with positron tomography. Use in normal subjects and in patients with schizophrenia. , 1982, Archives of general psychiatry.
[80] John P. Stack,et al. 1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: Clinical, neurodevelopmental, and cognitive correlates , 1994, Biological Psychiatry.
[81] M. Keshavan,et al. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. A pilot study of the dorsal prefrontal cortex by in vivo phosphorus 31 nuclear magnetic resonance spectroscopy. , 1991, Archives of general psychiatry.
[82] Jens Frahm,et al. Localized proton spectroscopy using stimulated echoes. , 1987 .
[83] B D Ross,et al. Absolute Quantitation of Water and Metabolites in the Human Brain. I. Compartments and Water , 1993 .
[84] A. Howseman,et al. 1H-[13C] NMR measurements of [4-13C]glutamate turnover in human brain. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[85] P. Slater,et al. Frontal Cortical and Left Temporal Glutamatergic Dysfunction in Schizophrenia , 1989, Journal of neurochemistry.
[86] J. Frahm,et al. Absolute concentrations of metabolites in the adult human brain in vivo: quantification of localized proton MR spectra. , 1993, Radiology.
[87] P. Williamson,et al. An in vivo study of the prefrontal cortex of schizophrenic patients at different stages of illness via phosphorus magnetic resonance spectroscopy. , 1995, Archives of general psychiatry.
[88] J. Macher,et al. Noninvasive in vivo detection of a fluorinated neuroleptic in the human brain by 19F nuclear magnetic resonance spectroscopy , 1990, Psychiatry Research: Neuroimaging.
[89] J. Cooper,et al. STUDIES ON THE FUNCTION OF N‐ACETYL ASPARTIC ACID IN BRAIN , 1965, Journal of neurochemistry.
[90] Z. Bhujwalla,et al. Determination of Absolute Phosphate Metabolite Concentrations in RIF‐1 Tumors in Vivo by 31P‐1H‐2H NMR Spectroscopy Using Water as an Internal Intensity Reference , 1992, Magnetic resonance in medicine.
[91] M. Abou-Saleh,et al. Psychiatry and the New Magnetic Resonance Era , 1990, British Journal of Psychiatry.
[92] P. Renshaw,et al. Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. , 1995, The American journal of psychiatry.
[93] R. Gupta,et al. NMR studies of intracellular metal ions in intact cells and tissues. , 1984, Annual review of biophysics and bioengineering.
[94] H. Nasrallah,et al. Corpus Callosum Thickness in Chronic Schizophrenia , 1983, British Journal of Psychiatry.
[95] P. Williamson,et al. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. , 1991, Archives of general psychiatry.
[96] D. Weinberger,et al. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. , 1986, Archives of general psychiatry.
[97] R. Mattson,et al. Localized 1H NMR measurements of gamma-aminobutyric acid in human brain in vivo. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[98] G. Radda,et al. Clinical aspects on 31P NMR spectroscopy. , 1984, British medical bulletin.
[99] G D Pearlson,et al. Auditory hallucinations and smaller superior temporal gyral volume in schizophrenia. , 1990, The American journal of psychiatry.
[100] L. DeLisi,et al. Glucose utilization in the temporal cortex of affectively ill patients: Positron emission tomography , 1987, Biological Psychiatry.
[101] J S Taylor,et al. Proton‐decoupled 31P chemical shift imaging of the human brain in normal volunteers , 1993, NMR in biomedicine.
[102] R G Shulman,et al. Spatially localized 1H NMR spectra of metabolites in the human brain. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[103] M. Martres,et al. Dopamine activation of the arachidonic acid cascade as a basis for D1D2 receptor synergism , 1991, Nature.
[104] A. Grace. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: A hypothesis for the etiology of schizophrenia , 1991, Neuroscience.
[105] N. Schuff,et al. 19F nuclear magnetic resonance spectroscopy of neuroleptics: The first in vivo pharmacokinetics of trifluoperazine in the rat brain and the first in vivo spectrum of fluphenazine in the human brain , 1991, Biological Psychiatry.
[106] Henry A. Nasrallah,et al. A controlled magnetic resonance imaging study of corpus callosum thickness in schizophrenia , 1986, Biological Psychiatry.
[107] K. Behar,et al. Short echo time proton magnetic resonance spectroscopic imaging of macromolecule and metabolite signal intensities in the human brain , 1996, Magnetic resonance in medicine.
[108] H. H. Kornhuber,et al. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia , 1980, Neuroscience Letters.
[109] G. Radda,et al. Phospholipid bilayer contribution to 31P NMR spectra in vivo , 1989, Magnetic resonance in medicine.
[110] A Carlsson,et al. The current status of the dopamine hypothesis of schizophrenia. , 1988, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.
[111] D. Sibley,et al. Expression of striatal D1 dopamine receptors coupled to inositol phosphate production and Ca2+ mobilization in Xenopus oocytes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[112] P. Williamson,et al. The use of a priori knowledge to quantify short echo in vivo 1h mr spectra , 1995, Magnetic resonance in medicine.
[113] A. Alavi,et al. Regional brain function in schizophrenia. I. A positron emission tomography study. , 1987, Archives of general psychiatry.
[114] P. Renshaw,et al. Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls , 1996, Schizophrenia Research.
[115] D. Gadian,et al. Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[116] A. Costello,et al. NON-INVASIVE INVESTIGATION OF CEREBRAL METABOLISM IN NEWBORN INFANTS BY PHOSPHORUS NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY , 1983, The Lancet.
[117] Paul A. Bottomley,et al. Depth-resolved surface-coil spectroscopy (DRESS) for in Vivo 1H, 31P, and 13C NMR , 1984 .
[118] C. Karson,et al. Detection of psychoactive drugs in vivo in humans using 19F NMR spectroscopy , 1991, Biological Psychiatry.
[119] D. Gadian,et al. Mapping of metabolites in whole animals by 31P NMR using surface coils , 1980, Nature.
[120] Martin H. Teicher,et al. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. , 1988, Archives of general psychiatry.
[121] P. Kinnunen,et al. Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy , 1987, Biological Psychiatry.
[122] G. Fein,et al. 31Phosphorus magnetic resonance spectroscopy of the temporal lobes in schizophrenia , 1992, Biological Psychiatry.